Literature DB >> 24497557

Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden.

Michele Baccarani1, Fabio Efficace, Gianantonio Rosti.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24497557      PMCID： PMC3912949          DOI： 10.3324/haematol.2013.094045

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  27 in total

1.  Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Hagop Kantarjian; Neil P Shah; Andreas Hochhaus; Jorge Cortes; Sandip Shah; Manuel Ayala; Beatriz Moiraghi; Zhixiang Shen; Jiri Mayer; Ricardo Pasquini; Hirohisa Nakamae; Françoise Huguet; Concepción Boqué; Charles Chuah; Eric Bleickardt; M Brigid Bradley-Garelik; Chao Zhu; Ted Szatrowski; David Shapiro; Michele Baccarani
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

2.  Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008.

Authors:  Magnus Björkholm; Lotta Ohm; Sandra Eloranta; Asa Derolf; Malin Hultcrantz; Jan Sjöberg; Therese Andersson; Martin Höglund; Johan Richter; Ola Landgren; Sigurdur Y Kristinsson; Paul W Dickman
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

3.  How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.

Authors:  Erik K Fromme; Kristine M Eilers; Motomi Mori; Yi-Ching Hsieh; Tomasz M Beer
Journal:  J Clin Oncol       Date:  2004-09-01       Impact factor: 44.544

Review 4.  Harmonization of molecular monitoring of CML therapy in Europe.

Authors:  M C Müller; N C P Cross; P Erben; T Schenk; B Hanfstein; T Ernst; R Hehlmann; S Branford; G Saglio; A Hochhaus
Journal:  Leukemia       Date:  2009-08-27       Impact factor: 11.528

Review 5.  Chronic myeloid leukaemia.

Authors:  Rüdiger Hehlmann; Andreas Hochhaus; Michele Baccarani
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

6.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

7.  Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

Authors:  R A Larson; A Hochhaus; T P Hughes; R E Clark; G Etienne; D-W Kim; I W Flinn; M Kurokawa; B Moiraghi; R Yu; R E Blakesley; N J Gallagher; G Saglio; H M Kantarjian
Journal:  Leukemia       Date:  2012-05-18       Impact factor: 11.528

8.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

9.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.

Authors: 
Journal:  Health Qual Life Outcomes       Date:  2006-10-11       Impact factor: 3.186

Review 10.  Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.

Authors:  Javier Pinilla-Ibarz; Jorge Cortes; Michael J Mauro
Journal:  Cancer       Date:  2010-10-04       Impact factor: 6.860
View more
  14 in total

1.  Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries.

Authors:  Jan Geissler; Giora Sharf; Felice Bombaci; Mina Daban; Jan De Jong; Tony Gavin; Jana Pelouchova; Euzebiusz Dziwinski; Joerg Hasford; Verena Sophia Hoffmann
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-13       Impact factor: 4.553

2.  Recovering from chronic myeloid leukemia: the patients' perspective seen through the lens of narrative medicine.

Authors:  G Graffigna; I Cecchini; M Breccia; E Capochiani; R Della Seta; S Galimberti; A Melosi; F Simonetti; M Pizzuti; S F Capalbo; F Falzetti; P Mazza; N Di Renzo; L Mastrullo; D Rapezzi; E Orlandi; T Intermesoli; A Iurlo; E Pungolino; M Pacilli
Journal:  Qual Life Res       Date:  2017-06-12       Impact factor: 4.147

Review 3.  The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors.

Authors:  Fabio Efficace; Laura Cannella
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

4.  A critical history of chromic myeloid leukemia.

Authors:  Michele Baccarani; Fabrizio Pane
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-01-02       Impact factor: 2.576

Review 5.  Treatment recommendations for chronic myeloid leukemia.

Authors:  Michele Baccarani; Fausto Castagnetti; Gabriele Gugliotta; Francesca Palandri; Gianantonio Rosti
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-01-02       Impact factor: 2.576

Review 6.  Pediatric Blood Cancer Survivors and Tobacco Use across Adolescence and Emerging Adulthood: A Narrative Review.

Authors:  Marianna Masiero; Silvia Riva; Chiara Fioretti; Gabriella Pravettoni
Journal:  Front Psychol       Date:  2016-03-21

Review 7.  Chronic Myeloid Leukemia in India.

Authors:  Prasanth Ganesan; Lalit Kumar
Journal:  J Glob Oncol       Date:  2016-07-20

8.  Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.

Authors:  Giuseppe Saglio; Philipp le Coutre; Jorge Cortes; Jiří Mayer; Philip Rowlings; François-Xavier Mahon; Glenn Kroog; Kyna Gooden; Milayna Subar; Neil P Shah
Journal:  Ann Hematol       Date:  2017-05-22       Impact factor: 3.673

9.  Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

Authors:  Neil P Shah; Philippe Rousselot; Charles Schiffer; Delphine Rea; Jorge E Cortes; Jorge Milone; Hesham Mohamed; Diane Healey; Hagop Kantarjian; Andreas Hochhaus; Giuseppe Saglio
Journal:  Am J Hematol       Date:  2016-06-20       Impact factor: 10.047

10.  Symptom Burden and Quality of Life Issues among Patients of Chronic Myeloid Leukemia on Long-term Imatinib Therapy.

Authors:  Radhika Unnikrishnan; Surendran Veeraiah; Prasanth Ganesan
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.